Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer

Authors :: Jean-Marc Phelip
Karine Le Malicot
Etienne Suc
François Ghiringhelli
Patrick Texereau
Eric Francois
Julien Taieb
Olivier Bouché
Françoise Desseigne
Faiza Khemissa
Valérie Boige
Jaafar Bennouna
Christian Borel
Jean-François Seitz
Dominique Genet
Jean-Louis Jouve
Stephane Jacquot
Thomas Aparicio
Roger Faroux
Source :: Journal of Clinical Oncology. 34:3531-3531
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 3531Background: Conflicting results are reported for maintenance treatment with bevacizumab (bev) during chemotherapy free intervals (CFI) in metastatic colorectal cancer (mCRC). Methods: The objec...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Bevacizumab
Colorectal cancer
business.industry
medicine.medical_treatment
medicine.disease
digestive system diseases
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
030211 gastroenterology & hepatology
business
medicine.drug

Full Text Access

Tools